Manager TitleAgeSince
Chief Executive Officer 62 06/01/2025
Director of Finance/CFO - 31/08/2014
Chief Operating Officer - 17/06/2024
Director TitleAgeSince
Director/Board Member - -
Director/Board Member 44 31/10/2020
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.17%+5.80% - - 409K
+5.91%-1.64%-17.69%+7.74% 121B
+0.30%+1.24%+4.38%-3.17% 13.07B
+2.26%+2.09%+60.72%+102.34% 9.21B
+9.11%+8.59%-45.41%-70.81% 4.2B
+3.08%+11.31%+15.91%+54.14% 2.91B
+3.86%-2.49%-15.39%-27.03% 1.73B
+1.54%+4.12%-5.20%-19.99% 1.67B
+3.95%+5.75%-12.67%-58.96% 1.47B
Average +3.24%+3.70%-1.92%-1.97% 19.45B
Weighted average by Cap. +4.69%-1.70%-11.10%+9.86%
Logo Endologix, Inc.
Endologix, Inc. develops, manufactures, markets and sells medical devices for the treatment of aortic disorders. The Company's products are designed for the minimally-invasive endovascular treatment of abdominal aortic aneurysms (AAA). Its AAA products are developed on one of two platforms: traditional minimally-invasive endovascular aneurysm repair (EVAR) or endovascular aneurysm sealing (EVAS), the Company's solution for sealing the aneurysm sac while maintaining blood flow. The Company's EVAR products include the AFX Endovascular AAA System (AFX System), the VELA Proximal Endograft (VELA) and the Ovation Abdominal Stent Graft System (Ovation System). The Company's EVAS product is the Nellix Endovascular Aneurysm Sealing System (the Nellix EVAS System).
Employees
-